The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children.
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe.
Department of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea.
Hyo Jin
0000-0001-5238-1931
HJ
Kwon
Department of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea.
Soo Young
0000-0002-5354-3135
SY
Lee
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Ki Hwan
0000-0001-6145-3909
KH
Kim
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Dong Soo
0000-0002-3270-506X
DS
Kim
Department of Pediatrics, Kyunghee University College of Medicine, Seoul, Korea.
Sung Ho
0000-0003-0540-5747
SH
Cha
Department of Pediatrics, Chonbuk National University College of Medicine, Jeonju, Korea.
Dae Sun
0000-0002-3141-9539
DS
Jo
Department of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea.
Jin Han
0000-0003-1610-6742
JH
Kang
D057134:Antibodies, Neutralizing / Q000032:analysis / Q000276:immunology; D000914:Antibodies, Viral / Q000032:analysis / Q000276:immunology; D000917:Antibody Formation; D002675:Child, Preschool; D015331:Cohort Studies; D004672:Encephalitis, Japanese / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007223:Infant; D022321:Japanese Encephalitis Vaccines / Q000276:immunology*; D008297:Male; D011446:Prospective Studies; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D022321:Japanese Encephalitis Vaccines; D014613:Vaccines, Attenuated
Children; Clinical Trial; Immunogenicity; Live Attenuated Japanese Encephalitis Vaccine; Safety